IP Verse

Methods Of Treating Lung Cancer - EP2968254

The patent EP2968254 was granted to Abraxis Bioscience on Apr 22, 2020. The application was originally filed on Mar 10, 2014 under application number EP14776420A. The patent is currently recorded with a legal status of "Revoked".

EP2968254

ABRAXIS BIOSCIENCE
Application Number
EP14776420A
Filing Date
Mar 10, 2014
Status
Revoked
Jul 7, 2023
Publication Date
Apr 22, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

TEVA PHARMACEUTICALSJan 19, 2021D YOUNGADMISSIBLE

Patent Citations (11) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS2006263434
DESCRIPTIONUS2007082838
DESCRIPTIONUS5916596
DESCRIPTIONUS6096331
DESCRIPTIONUS6506405
DESCRIPTIONUS6537579
DESCRIPTIONUS6749868
DESCRIPTIONUS7820788
DESCRIPTIONUS8034375
DESCRIPTIONWO2008137148
OPPOSITIONUS8143236

Non-Patent Literature (NPL) Citations (61) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- ALLERTON J.P. et al., "ASCO Annual Meeting Proceedings", J Clin Oneol., (20060000), vol. 24, no. 18S, page 7127
DESCRIPTION- BELANI CP; FOSSELLA F, "Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced non-small cell lung carcinoma (TAX 326", Cancer, (20050000), vol. 104, pages 2766 - 2774
DESCRIPTION- BELANI et al., J Clin Oncol., (20080000), vol. 26, no. 3, pages 468 - 473
DESCRIPTION- CARTER et al., Adv. Protein. Chem., (19940000), vol. 45, pages 153 - 203
DESCRIPTION- CURRY et al., Nat. Struct. Biol., (19980000), vol. 5, pages 827 - 35
DESCRIPTION- DEPIERRE A. et al., Proc ASCO, (19880000), vol. 7, page 201
DESCRIPTION- DESAI et al., Clin Cancer Res, (20060000), vol. 12, no. 4, pages 1317 - 1324
DESCRIPTION- DUBEY S.; SCHILLER J.H., Hematol Oncol Clin N Am., (20040000), vol. 18, pages 101 - 114
DESCRIPTION- FEHSKE et al., Biochem. Pharmeol., vol. 30, pages 687 - 92
DESCRIPTION- FINLAYSON, Seminars in Thrombosis and Hemostasis, (19800000), vol. 6, pages 85 - 120
DESCRIPTION- GELDERBLOM H. et al., Eur J Cancer., (20010000), vol. 37, pages 1590 - 8
DESCRIPTION- GREEN M.R. et al., Ann Oncol., (20060000), vol. 17, pages 1263 - 8
DESCRIPTION- GRIDELLI C., "Does chemotherapy have a role as palliative therapy for unfit or elderly patients with non-small cell lung cancer?", Lung Cancer, (20020000), vol. 28, pages S45 - S50
DESCRIPTION- HAWKINS M.J. et al., "ASCO Annual Meeting Proceedings", J Clin Oneol., (20060000), vol. 24, no. 18S, page 7132
DESCRIPTION- HE et al., Nature, vol. 358, pages 209 - 15
DESCRIPTION- HERBST R.S. et al., J Clin Oncol., (20040000), vol. 22, pages 785 - 794
DESCRIPTION- HOUSER et al., Surgery, Gynecology and Obstetrics, (19800000), vol. 150, pages 811 - 816
DESCRIPTION- KELLY K. et al., J Clin Oncol., (20010000), vol. 19, pages 3210 - 3218
DESCRIPTION- KOUKOURAKIS et al., Cancer Research, (20030000), vol. 63, pages 53756 - 5380
DESCRIPTION- KRAGH-HANSEN, Dan. Med. Bull., (19900000), vol. 1441, pages 131 - 40
DESCRIPTION- KUDOH S; TAKEDA K; NAKAGAWA K et al., "Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904", J Clin Oncol., (20060000), vol. 24, pages 3657 - 3663
DESCRIPTION- LILENBAUM RC; HERNDON JE 2ND; LIST MA et al., "Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the Cancer and Leukemia Group B (study 9730", J Clin Oncol., (20050000), vol. 23, pages 190 - 196
DESCRIPTION- LORENZ W. et al., Agents and Actions, (19770000), vol. 7, pages 63 - 67
DESCRIPTION- LYNCH et al., J Clin Oncol., (20100000), vol. 28, no. 6, pages 911 - 917
DESCRIPTION- PAAL et al., Eur. J. Biochem., vol. 268, no. 7, pages 2187 - 91
DESCRIPTION- PORTER et al., J. Histochem. Cytochem., (19950000), vol. 43, page 791
DESCRIPTION- QUIOX E., "Optimal pharmacotherapeutic strategies for elderly patients with advanced non-small cell lung cancer", Drugs Aging., (20110000), vol. 28, pages 885 - 894
DESCRIPTION- QUOIX E; ZALCMAN G; OSTER JP et al., "Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomized, phase 3 trial", Lancet, (20110000), vol. 378, pages 1079 - 1088
DESCRIPTION- RIZVI N.A. et al., "ASCO Annual Meeting Proceedings", J Clin Oneol., (20060000), vol. 24, no. 18S, page 7105
DESCRIPTION- SCAGLIOTTI et al., J Clin Oncol., (20080000), vol. 26, no. 21, pages 3543 - 3551
DESCRIPTION- SCAGLIOTTI G.V. et al., J Clin Oncol., (20020000), vol. 20, pages 4285 - 4291
DESCRIPTION- SCHILLER J.H. et al., N Engl J Med., (20020000), vol. 346, pages 92 - 98
DESCRIPTION- SEER Cancer Statistics Review, National Cancer Institute, pages 1975 - 2008
DESCRIPTION- SOCINSKI et al., Journal of Clinical Oncology, (20120000), vol. 30, no. 17, pages 2055 - 2062
DESCRIPTION- SPARREBOOM A. et al., Cancer Res., (19990000), vol. 59, no. 7, pages 1454 - 1457
DESCRIPTION- SUGIO et al., Protein. Eng., (19990000), vol. 12, pages 439 - 46
DESCRIPTION- TEN TIJE A.J. et al., Clin Pharmacokinet, (20030000), vol. 42, pages 665 - 85
DESCRIPTION- TEN TIJE A.J. et al., Clin Pharmacokinet., (20030000), vol. 42, pages 665 - 85
DESCRIPTION- THERASSE P. et al., J Natl Cancer Inst., (20000000), vol. 92, pages 205 - 216
DESCRIPTION- TIJE A.J. et al., Clin Pharmacokinet., (20030000), vol. 42, pages 665 - 85
DESCRIPTION- TULLIS, JAMA, (19770000), vol. 237, pages 355 - 360,460-463
DESCRIPTION- VAN TELLINGEN O. et al., Br J Cancer, (19990000), vol. 81, pages 330 - 5
DESCRIPTION- VORUM, Dan. Med. Bull., (19990000), vol. 46, pages 379 - 99
DESCRIPTION- WEISS R.B. et al., J Clin Oncol., (19900000), vol. 8, pages 1263 - 1268
DESCRIPTION- WINER E. et al., Proceedings of ASCO, (19980000), vol. 17
DESCRIPTION- YOO et al., Lung Cancer, (20030000), vol. 42, pages 195 - 202
DESCRIPTION- MIELKE S; SPARREBOOM A; MROSS K, "Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes", Eur J Cancer, (20060000), vol. 42, doi:doi:10.1016/j.ejca.2005.06.030, pages 24 - 30, XP025104360
DESCRIPTION- SOCINSKI MA; BONDARENKO I; KARASEVA NA et al., "Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial", J Clin Oncol., (20120000), vol. 30, doi:doi:10.1200/JCO.2011.39.5848, pages 2055 - 2062, XP055310043
INTERNATIONAL-SEARCH-REPORT- DESAI, N. ET AL., "Nab Technology: A Drug Delivery Platform Utilising Endothelial gp60 Receptor-based Transport and' Tumour-derived SPARC for Targeting", DRUG DELIVERY REPORT WINTER, (20070101), pages 37 - 41, URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/UCM289191.pdf, (20140604), XP055287846
INTERNATIONAL-SEARCH-REPORT- SOCINSKI, M.A ET AL., "Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small- cell lung cancer", ANNALS OF ONCOLOGY, (20130201), vol. 24, no. 2, doi:10.1093/ANNONC/MDS461, pages 314 - 321, XP055287824
INTERNATIONAL-SEARCH-REPORT- REYNOLDS, C. ET AL., "Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non- small Cell Lung Cancer", JOURNAL OF THORACIC ONCOLOGY, (20091201), vol. 4, no. 12, doi:10.1097/JTO.0B013E3181C0A2F4, pages 1537 - 1543, XP008163850
OPPOSITION- Clinical pharmacology of cancer therapies in older adults, "Clinical pharmacology of cancer therapies in older adults", British Journal of Cancer, (20080000), vol. 98, pages 517 - 522, XP055780971
OPPOSITION- Hirsh Vera , Amy Ko , Richard Pilot , Markus F Renschler , Mark A Socinski, "Weekly nab-Paclitaxel in Combination With Carboplatin as First- Line Therapy in Patients With Advanced NoneSmall- Cell Lung Cancer: Analysis of Safety and Efficacy in Patients With Diabetes", Clinical Lung Cancer, (20160000), vol. 17, no. 5, pages 367 - 374, XP055780976
OPPOSITION- Qi Zheng 1, Yu Yao, Kejun Nan, "Weekly intravenous nanoparticle albumin-bound paclitaxel for elderly patients with stage IV non-small- cell lung cancer: a series of 20 cases", Journal of Biomedical Research, (20120000), vol. 26, no. 3, pages 159 - 164, XP055780967
OPPOSITION- Rossi David, Donatella Dennetta, Marcello Ugolini, Paolo Alessandroni, Vincenzo Catalano, Stefano Luzi Fedeli, Paolo Giordani, Virginia Casadei, Anna Maria Baldelli, Francesco Graziano, Giuseppina Catalano, "Weekly Paclitaxel in Elderly Patients (Aged ? 70 Years) with Advanced Non-Small- Cell Lung Cancer: An Alternative Choice? Results of a Phase II Study", Clinical Lung Cancer, (20080000), vol. 9, no. 5, pages 280 - 284, XP055780982
OPPOSITION- QUASTHOFF et al., "Chemotherapy-induced peripheral neuropathy", J Neurol, (20020000), vol. 249, doi:10.1007/PL00007853, pages 9 - 17, XP001104073
OPPOSITION- SOCINSKI et al., "Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non- small- cell lung cancer", Annals of Oncology, (20121102), vol. 24, doi:10.1093/annonc/mds461, pages 314 - 321, XP055287824
OPPOSITION- REYNOLDS et al., "Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell Lung Cancer", J Thorac Oncol, (20090000), vol. 4, doi:10.1097/JTO.0b013e3181c0a2f4, pages 1537 - 1543, XP008163102
OPPOSITION- KALEY et al., "Therapy of chemotherapy-induced peripheral neuropathy", British Journal of Haematology, (20090000), vol. 145, doi:10.1111/j.1365-2141.2008.07558.x, pages 3 - 14, XP055191567
OPPOSITION- SOCINSKI et al., "Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non-Small- Cell Lung Cancer: Final Results of a Phase III Trial", J Clin Oncol, (20120000), vol. 30, doi:10.1200/JCO.2011.39.5848, pages 2055 - 2062, XP055310043
SEARCH- M. A. SOCINSKI ET AL, "Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Final Results of a Phase III Trial", JOURNAL OF CLINICAL ONCOLOGY, US, (20120430), vol. 30, no. 17, doi:10.1200/JCO.2011.39.5848, ISSN 0732-183X, pages 2055 - 2062, XP055310043 [I] 1-15 * page 2056 - page 2057, paragraph 4 * * page 2058, column l, paragraph l * * figure 3 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents